Physician profile
Barbara E Fahey
NPI 1689671703
$2,750.08
in general payments reported to CMS, 2019-2025
28 companies · $648 in 2025
The $648 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $316 · 2022: $804 · 2023: $443 · 2024: $539 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,630.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $670.92 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $570.54 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $229.08 | 2024-2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $217.49 | 2022-2025 | Arexvy, Shingrix, Bexsero |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $190.99 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $123.09 | 2022 | |
| Lilly USA, LLC | $89.71 | 2021-2025 | Mounjaro |
| Pfizer INC. | $74.74 | 2023-2025 | |
| Scpharmaceuticals INC. | $64.26 | 2025 | |
| Merck Sharp & Dohme LLC | $57.55 | 2021-2025 | Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.02 | 2021-2022 | |
| Amgen INC. | $49.40 | 2021-2023 | Otezla, Repatha |
| Corcept Therapeutics | $35.14 | 2025 | Korlym |
| Edwards Lifesciences Corporation | $33.48 | 2023 | |
| Hologic Sales and Service, LLC | $29.45 | 2023 | Aptima, Thinprep 2000 Processor |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27.92 | 2021-2024 | Farxiga |
| Exact Sciences Corporation | $26.73 | 2023 | Cologuard Collection Kit |
| Organon LLC | $22.14 | 2021 | |
| Lundbeck LLC | $22.02 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $21.30 | 2024 | |
| Jazz Pharmaceuticals INC. | $20.94 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $20.69 | 2022 | |
| Axsome Therapeutics, INC. | $20.50 | 2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $18.07 | 2021 | |
| Phadia US INC. | $17.89 | 2024 | Immunocap |
| Phathom Pharmaceuticals, INC. | $15.48 | 2024 | Voquezna |
| Gilead Sciences, INC. | $13.35 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Fahey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.